ASMB (Assembly Bio) Earnings per share for the last twelve months

Public company logo of Assembly Biosciences Inc (ASMB)

Assembly Biosciences (ASMB) delegates the synthesis of trial drug batches to external laboratories, flexibly rotating suppliers. The business relies on US-based R&D centers, outsourcing the production of small molecules against hepatitis B to contract manufacturing organizations. This chart of EPS (TTM) price action reflects a level of 97.80. The firm's strategy focuses on creating innovative agents that suppress viral replication, leveraging partners to optimize testing expenses.

assemblybio.com (ASMB): Earnings per share for the last twelve months from 02/11/2024 to 11/12/2026

ASMB (Assembly Biosciences Inc): analytical breakdowns and indicator data

- market price and analyst price targets:
Market Chart assemblybio.com|ASMB - Consensus Target
- business market valuation indicators:
Market Value Assembly Bio|ASMB - Enterprise Value
- balance sheet net asset value indicators:
Net Asset Value per Share Assembly Biosciences|ASMB - Company Book Value|Market Value to Book Value assemblybio.com|ASMB - Company Total Assets
- company total debt and liquidity indicators:
Total Debt to Capital Assembly Biosciences|ASMB - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Assembly Corp|ASMB - Company Debts|Debts to Net Assets Assembly Bio|ASMB - Company Long-Term Debts|Short-Term Debt Assembly Biosciences|Quick Liquidity Indicator assemblybio.com
- net income and valuation ratios data:
ASMB - Net Profit|Expected Profit Assembly Biosciences|ASMB - Price to Earnings Ratio|Future Price to Earnings Assembly Bio|ASMB - Price/Earnings to Growth Multiple|Company Value to EBITDA Assembly Bio|ASMB - Operating profit before deduction of amortization|Earnings per share for the trailing year Assembly Biosciences|ASMB - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months assemblybio.com|ASMB - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Assembly Biosciences
Initial company analysis:ASMB (assemblybio.com)
Mass-produced product of Assembly Biosciences

Year-over-year (TTM) EPS growth measures the dynamics of net income per share by comparing the current twelve-month period with the same period last year. Professionals utilize this rate to assess capitalization efficiency and the sustainability of cash flows. By analyzing historical year-over-year (TTM) EPS growth, an investor determines the fairness of a business's market value. For Assembly Biosciences (ASMB), this indicator is critical as it reflects financial viability amidst fierce competition with pharmaceutical behemoths.

Competitor analysis for Assembly Biosciences

Net earnings per share for the last four quarters arrowheadpharma.com ARWR|MIRM (Mirum) - Net earnings per share for the last 12 months|DVAX (Dynavax Pharma) - Earnings per share for the last twelve months|ABUS (Arbutus) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Inventiva Corp IVA|Earnings per share for the last twelve months Gyre Therapeutics, Inc. (GYRE)|GALT (galectintherapeutics.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) GNFT (GENFIT)|Net earnings per share (EPS TTM) DURECT Corp DRRX|ALGS - Earnings per share for the last twelve months|Net earnings per share for the last four quarters BioVie Inc. BIVI|galmedpharma.com (GLMD) - Earnings per share for the last twelve months|NDRA - Net earnings per share for the last four quarters|HEPA (Hepion Pharmaceuticals Inc.) - Net earnings per share (EPS TTM)